Ritedose Pharmaceuticals Launches Budesonide Inhalation Suspension (0.5 mg/2 ml)

COLUMBIA, S.C. (December 29, 2021) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product for hospitals, Budesonide Inhalation Suspension (0.5 mg/2 ml). It is the first of five new inhalation products scheduled for release by March 2022. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.

The Budesonide inhalation suspension comes with 30 single-dose ampules per carton, all individually wrapped and barcoded. It is available in hospital and institutional packaging and can be ordered along with all other Ritedose hospital products, including 503B medications, through an online customer portal. It is also available for ordering through pharmaceutical wholesalers.

“We’re pleased to add products that complement our already robust inhalation portfolio,” said Ritedose President and CEO Jody Chastain. “With our manufacturing capabilities and annual capacity, we offer our hospital clients an ample, reliable supply of the many products they regularly need.”

Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and packaging of single-dose medication, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 25-year track record includes delivery of more than 8 billion doses since 2012 without a single recall, and its current capacity is 2.1 billion units annually. To request more information on Ritedose products or to place an order or contact us.

Pioneers in aseptic production of sterile, single-dose medication